Showing 4211-4220 of 8897 results for "".
- Retin-A Micro Gel Microsphere 0.06% Now Available from Ortho Dermatologics to Treat Acnehttps://practicaldermatology.com/news/retin-a-micro-gel-microsphere-006-now-available-from-ortho-dermatologics-to-treat-acne/2457914/Retin-A Micro (tretinoin) gel microsphere 0.06% is now available commercially to healthcare professionals. The FDA approved Ortho Dermatologics' Supplemental New Drug Application (sNDA) for Retin-A Micro (tretinoin) gel microsphere 0.06% for topical application in the treatment of acne vulgar
- Meet JAAD's New Editor Dirk M. Elston, MDhttps://practicaldermatology.com/news/meet-jaads-new-editor-dirk-m-elston-md/2457918/Charleston, SC-based dermatologist Dirk M. Elston, MD, FAAD, is the next editor of the Journal of the American Academy of Dermatology. Dr. Elston, the journal’s current deputy editor, will step into his new role in July 2018, succeeding de
- New Research Explains Why Women Who Have Been Pregnant Have Better Melanoma Outcomeshttps://practicaldermatology.com/news/new-research-explains-why-women-who-have-been-pregnant-have-better-melanoma-outcomes/2457922/For decades, research has associated female sex and a history of previous pregnancy with better outcomes after a melanoma diagnosis. Now, a research team from Perelman School of Medicine at the University of Pennsylvania says it may have determined the reason for the melanoma-protective effect.</
- New from Nerium: Prolistic Probiotic Productshttps://practicaldermatology.com/news/new-from-nerium-prolistic-probiotic-products/2457921/Nerium International is rolling out Prolistic™ Pre & Probiotic Plus Vitamins powder packets and Prolistic™Skin-Balancing Lotion with Probiotic Technology. The new Prolistic Pre & Probiotic Plus Vitamins powder
- New Ceramide-Infused Skin Barrier Product Reduces Costs for Ostomy Carehttps://practicaldermatology.com/news/new-ceramide-infused-skin-barrier-product-reduces-costs-for-ostomy-care/2457929/Ostomy patients using a new type of skin barrier product infused with ceramides may experience lower costs of care, according to a randomized trial published
- AAD Issues New Guidelines for Treatment of Non-melanoma Skin Cancerhttps://practicaldermatology.com/news/aad-issues-new-guidelines-for-treatment-of-non-melanoma-skin-cancer/2457928/The American Academy of Dermatology (AAD) has addressed the growing health concern about non-melanoma skin cancers (NMSC) with the release of its guidelines of care for the management of basal cell carcinoma and cutaneous squamous cell carcinoma, published online in the Journal of the Am
- Nailed It: Researchers Unveil Fingernail-Sized UV Sensor at CEShttps://practicaldermatology.com/news/nailed-it-researchers-unveil-fingernail-sized-uv-sensor-at-ces/2457931/Northwestern University researchers and L’Oréal have nailed it. Working together, they developed a wafer-thin, feather-light sensor can fit on a fingernail and precisely measures a person’s exposure to UV light from the sun. The device, as light as a raindrop an
- New AD Yardstick Highlights Treatment Advanceshttps://practicaldermatology.com/news/new-ad-yardstick-highlights-treatment-advances/2457933/Treatment for atopic dermatitis (AD) has changed a lot in the last few years, according to a new yardstick published in Annals of Allergy, Asthma and Immunology. “The Atopic Dermatitis Yardstick
- DermTech Receives Health Canada Approval to Market PLA and Non-invasive Biopsy Kithttps://practicaldermatology.com/news/dermtech-receives-health-canada-approval-to-market-pla-and-non-invasive-biopsy-kit/2457937/DermTech, Inc's licensee, DermTech Canada Inc., has received approval to market DermTech’s Pigmented Lesions Assay (PLA) and non-invasive biopsy kit for the detection of melanoma in Canada. DermTech Canada will market and sell the PLA, and samples will be processed at DermTech’s c
- FDA Approves BMS's Opdivo as Adjuvant Therapy in Patients with Completely Resected Melanoma with Lymph Node Involvement or Metastatic Diseasehttps://practicaldermatology.com/news/fda-approves-bmss-opdivo-as-adjuvant-therapy-in-patients-with-completely-resected-melanoma-with-lymph-node-involvement-or-metastatic-disease/2457941/The FDA has approved Bristol-Myers Squibb Company's Opdivo (nivolumab) injection for intravenous use for the adjuvant treatment of patients with melanoma with involvement of lymph nodes or metastatic disease who have undergone complete resection. The purpose of adjuvant therapy is to reduce t